Annika Bergquist

12.1k total citations · 4 hit papers
149 papers, 5.8k citations indexed

About

Annika Bergquist is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Annika Bergquist has authored 149 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 122 papers in Hepatology, 71 papers in Epidemiology and 69 papers in Surgery. Recurrent topics in Annika Bergquist's work include Liver Diseases and Immunity (115 papers), Liver Disease Diagnosis and Treatment (66 papers) and Gallbladder and Bile Duct Disorders (59 papers). Annika Bergquist is often cited by papers focused on Liver Diseases and Immunity (115 papers), Liver Disease Diagnosis and Treatment (66 papers) and Gallbladder and Bile Duct Disorders (59 papers). Annika Bergquist collaborates with scholars based in Sweden, Norway and United States. Annika Bergquist's co-authors include Ulrika Broomé, Erik von Seth, Kirsten Muri Boberg, Hans Glaumann, Sven Almér, Stefan Lindgren, Rolf Hultcrantz, Hanne Prytz, Hanna Sandberg–Gertzén and Tom H. Karlsen and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and PLoS ONE.

In The Last Decade

Annika Bergquist

140 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epidemiology of cholangiocarcinoma

2015 295 citations Annika Bergquist, Erik von Seth profile →
EASL Clinical Practice Guidelines on sclerosing cholangitis

2022 175 citations Annika Bergquist, Tom H. Karlsen et al. Journal of Hepatology profile →
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma

2022 152 citations Christopher L. Bowlus, Annika Bergquist et al. Hepatology profile →
Primary sclerosing cholangitis

2025 13 citations Annika Bergquist, Tom H. Karlsen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Annika Bergquist Sweden	42	3.9k	3.3k	2.4k	2.1k	776	149	5.8k
Ulrika Broomé Sweden	48	4.4k 1.2×	3.4k 1.1×	2.8k 1.2×	2.3k 1.1×	807 1.0×	101	6.7k
Kirsten Muri Boberg Norway	45	5.5k 1.4×	3.7k 1.1×	3.5k 1.5×	2.0k 1.0×	699 0.9×	109	7.4k
Atsushi Tanaka Japan	37	2.9k 0.7×	1.9k 0.6×	2.5k 1.0×	817 0.4×	490 0.6×	197	4.5k
Cynthia Levy United States	37	3.2k 0.8×	2.1k 0.6×	2.5k 1.0×	846 0.4×	894 1.2×	179	4.4k
Raoul Poupon France	43	5.7k 1.5×	3.2k 1.0×	5.0k 2.0×	839 0.4×	1.5k 1.9×	90	7.9k
Henk R. van Buuren Netherlands	37	3.5k 0.9×	2.6k 0.8×	2.8k 1.1×	1.1k 0.5×	745 1.0×	134	5.0k
Denise M. Harnois United States	34	3.2k 0.8×	2.6k 0.8×	2.2k 0.9×	1.1k 0.5×	944 1.2×	110	5.1k
Mariana Berho United States	34	1.5k 0.4×	1.9k 0.6×	1.9k 0.8×	451 0.2×	1.3k 1.7×	116	5.1k
Mauro Salizzoni Italy	43	4.2k 1.1×	3.3k 1.0×	3.7k 1.5×	510 0.2×	473 0.6×	202	7.2k
Takashi Matsumata Japan	39	3.0k 0.8×	2.2k 0.7×	1.5k 0.6×	1.0k 0.5×	1.4k 1.8×	192	5.2k

Countries citing papers authored by Annika Bergquist

Since Specialization

Citations

This map shows the geographic impact of Annika Bergquist's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annika Bergquist with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annika Bergquist more than expected).

Fields of papers citing papers by Annika Bergquist

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annika Bergquist. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annika Bergquist. The network helps show where Annika Bergquist may publish in the future.

Co-authorship network of co-authors of Annika Bergquist

This figure shows the co-authorship network connecting the top 25 collaborators of Annika Bergquist. A scholar is included among the top collaborators of Annika Bergquist based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annika Bergquist. Annika Bergquist is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Holmer, Magnus, Michael Ingre, Martti Färkkilâ, et al.. (2025). Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study. Hepatology. 83(1). 21–29.

Mol, Bregje, Martti Färkkilâ, Trine Folseraas, et al.. (2024). DOP14 Proctocolectomy is associated with improved transplant-free survival in patients with primary sclerosing cholangitis: results from a pooled collaborative international study. Journal of Crohn s and Colitis. 18(Supplement_1). i97–i98. 2 indexed citations

Casswall, Thomas, et al.. (2024). Good long-term outcomes of primary sclerosing cholangitis in childhood. JHEP Reports. 6(8). 101123–101123. 1 indexed citations

Bergquist, Annika, Mattias Ekstedt, Hannes Hagström, et al.. (2024). Forty years of successful national research collaboration in liver disease – the Swedish experience. Scandinavian Journal of Gastroenterology. 59(12). 1314–1321. 1 indexed citations

Cornillet, Martin, Daniel Geanon, Annika Bergquist, & Niklas K. Björkström. (2024). Immunobiology of primary sclerosing cholangitis. Hepatology. 82(4). 911–926. 5 indexed citations

Hussain, Nasir, Christopher Ma, Gideon M. Hirschfield, et al.. (2024). Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis. BMJ Open. 14(6). e080143–e080143. 3 indexed citations

Jiang, Xiaojun, Kari Otterdal, Brian K. Chung, et al.. (2023). Cholangiocytes Modulate CD100 Expression in the Liver and Facilitate Pathogenic T-Helper 17 Cell Differentiation. Gastroenterology. 166(4). 667–679. 5 indexed citations

Bergquist, Annika, et al.. (2023). Inflammatory bowel disease and primary sclerosing cholangitis: One disease or two?. Journal of Hepatology. 80(1). 155–168. 31 indexed citations

Carbone, Marco, Chiara Mazzarelli, Eléonora De Martin, et al.. (2023). Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)—A European Society of Organ Transplantation (ESOT) Consensus Statement. Transplant International. 36. 11729–11729. 8 indexed citations

10.

Bergquist, Annika, Hanns–Ulrich Marschall, Emma Nilsson, et al.. (2022). Long Term Effect of Simvastatin in Primary Sclerosing Cholangitits: A Placebo-Controlled, Double-Blind, Multicenter Phase III Study (Piscatin). 4(1). 6 indexed citations

11.

Ringe, Kristina I., Johan Bengtsson, Cecilia Forsman, et al.. (2022). Development of a prognostic MRCP-score (DiStrict) for individuals with large-duct primary sclerosing cholangitis. JHEP Reports. 4(12). 100595–100595. 16 indexed citations

12.

Zimmer, Christine L., Iva Filipovic, Martin Cornillet, et al.. (2021). Mucosal‐associated invariant T‐cell tumor infiltration predicts long‐term survival in cholangiocarcinoma. Hepatology. 75(5). 1154–1168. 26 indexed citations

13.

Jiang, Xiaojun, Annika Bergquist, Britt-Sabina Löscher, et al.. (2021). A heterozygous germline CD100 mutation in a family with primary sclerosing cholangitis. Science Translational Medicine. 13(582). 15 indexed citations

14.

Seth, Erik von, Katalin Dobra, Anders Hjerpe, et al.. (2018). Diagnostic performance of a stepwise cytological algorithm for biliary malignancy in primary sclerosing cholangitis. Liver International. 39(2). 382–388. 14 indexed citations

15.

Seth, Erik von, Christine L. Zimmer, Urban Arnelo, et al.. (2018). Primary sclerosing cholangitis leads to dysfunction and loss of MAIT cells. European Journal of Immunology. 48(12). 1997–2004. 32 indexed citations

16.

Forkel, Marianne, Lena Berglin, Eliisa Kekäläinen, et al.. (2017). Composition and functionality of the intrahepatic innate lymphoid cell‐compartment in human nonfibrotic and fibrotic livers. European Journal of Immunology. 47(8). 1280–1294. 55 indexed citations

17.

Marschall, Hanns–Ulrich, Annika Bergquist, Fredrik Rorsman, et al.. (2017). Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis. Scandinavian Journal of Gastroenterology. 52(9). 1–7. 40 indexed citations

18.

Lindström, Linda S., Kirsten Muri Boberg, Ola Wikman, et al.. (2012). High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Alimentary Pharmacology & Therapeutics. 35(4). 451–457. 58 indexed citations

19.

Hov, Johannes R., Vasilis Kosmoliaptsis, Marita Olsson, et al.. (2011). 22 ELECTROSTATIC MODIFICATIONS OF THE HLA-DR P9 PEPTIDE-BINDING POCKET AND SUSCEPTIBILITY TO PRIMARY SCLEROSING CHOLANGITIS. Journal of Hepatology. 54. S10–S11. 5 indexed citations

20.

Rajani, Ravi R., Einar S. Björnsson, Annika Bergquist, et al.. (2010). The epidemiology and clinical features of portal vein thrombosis: a multicentre study. Alimentary Pharmacology & Therapeutics. 32(9). 1154–1162. 127 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact